Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Pyrazinamide resistance in rifampicin discordant tuberculosis.

PloS one - 1 Jan 2022

Mvelase Nomonde Ritta, Singh Ravesh, Swe Swe-Han Khine, Mlisana Koleka Patience

Abstract excerpt

INTRODUCTION: Mycobacterium tuberculosis strains with phenotypically susceptible rpoB mutations (rifampicin discordant) have emerged following implementation of rapid molecular drug resistance testing for tuberculosis. Whilst rifampicin resistance is known to be associated with resistance to other rifamycins (rifapentine and rifabutin) as well as isoniazid and pyrazinamide, rifampicin discordant strains have...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antitubercular Agents
Share to Isoniazid
Share to Mycobacterium tuberculosis

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Pyrazinamide

Share to Rifampin

Share to South Africa

Share to Tuberculosis

Share to Tuberculosis, Multidrug-Resistant

Source

Open in PubMed Open full text

Identifiers

PMID: 36129921
DOI: 10.1371/journal.pone.0274688
PMCID: PMC9491533

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Pyrazinamide resistance in rifampicin discordant tuberculosis.PMID 36129921Read ↗

rpoB Mutations Causing Discordant Rifampicin Susceptibility in Mycobacterium tuberculosis: Retrospective Analysis of Prevalence, Phenotypic, Genotypic, and Treatment OutcomesSemantic proximity Read ↗

Frequency and implications of pyrazinamide resistance in managing previously treated tuberculosis patients.Semantic proximity Read ↗

Overcoming the Challenges of Pyrazinamide Susceptibility Testing in Clinical Mycobacterium tuberculosis Isolates.Semantic proximity Read ↗

Prevalence of pyrazinamide resistance across the spectrum of drug resistant phenotypes of Mycobacterium tuberculosis.Semantic proximity Read ↗

Comparative Performance of Genomic Methods for the Detection of Pyrazinamide Resistance and Heteroresistance in Mycobacterium tuberculosis.Semantic proximity Read ↗

Pyrazinamide resistance among South African multidrug-resistant Mycobacterium tuberculosis isolates.Semantic proximity Read ↗

Occurrence of disputed rpoB mutations among Mycobacterium tuberculosis isolates phenotypically susceptible to rifampicin in a country with a low incidence of multidrug-resistant tuberculosisSemantic proximity Read ↗

Detection of Pyrazinamide Heteroresistance in Mycobacterium tuberculosis.Semantic proximity Read ↗

High prevalence of phenotypic pyrazinamide resistance and its association with pncA gene mutations in Mycobacterium tuberculosis isolates from Uganda.Semantic proximity Read ↗

Rapid diagnosis of pyrazinamide-resistant multidrug-resistant tuberculosis using a molecular-based diagnostic algorithm.Semantic proximity Read ↗

Consequences of rpoB mutations missed by the GenoType MTBDRplus assay in a programmatic setting in South AfricaSemantic proximity Read ↗

High Prevalence of inhA Promoter Mutations among Patients with Drug-Resistant Tuberculosis in KwaZulu-Natal, South Africa.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.